other material
confidence high
sentiment positive
materiality 0.65
AbbVie extends option for Aldeyra's reproxalap with $5M fee
Aldeyra Therapeutics, Inc.
- AbbVie paid $5M non-refundable fee to extend option period for reproxalap co-development license.
- Exercise period now until 10 business days after FDA approval or 18 months from Oct 31, 2023.
- Option fee will be credited against upfront cash if License Agreement is signed.
- Reproxalap is Aldeyra's NDA-stage treatment for dry eye disease.